To Be 17 Again - Anti-Interleukin-17 Treatment for Psoriasis

被引：44
|
作者：
Waisman, Ari [1 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Inst Mol Med, Univ Med Ctr, Mainz, Germany
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 366卷 / 13期
关键词：
IL-17 CYTOKINE FAMILY; SKIN INFLAMMATION; HOST-DEFENSE; T-CELL; MICE; INTERLEUKIN-22; REQUIREMENT; DISEASES; IL-22;
D O I：
10.1056/NEJMe1201071
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1251 / 1252
页数：2
相关论文
共 50 条
  • [21] Interleukin 17-A inhibition in the treatment of psoriasis
    Yiu, Zenas Z. N.
    Griffiths, Christopher E. M.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (01) : 1 - 4
  • [22] Targeting of interleukin-17 in the treatment of psoriasis
    Lonnberg, Ann Sophie
    Zachariae, Claus
    Skov, Lone
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2014, 7 : 251 - 259
  • [23] Interleukin-17 Antagonists in the Treatment of Psoriasis
    Chandrakumar, Shivani Felicia
    Yeung, Jensen
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2015, 19 (02) : 109 - 114
  • [24] Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis
    Genovese, Mark C.
    Mease, Philip J.
    Greenwald, Maria W.
    Ritchlin, Christopher T.
    Beaulieu, Andre
    Deodhar, Atul
    Newmark, Richard
    Feng, JingYuan
    Erondu, Ngozi
    Nirula, Ajay
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S347 - S348
  • [25] Is an anti-interleukin-17 receptor able to do the job when an anti-interleukin-12/23 has failed?
    Montaudie, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (02) : 255 - 256
  • [26] A Phase 2 trial of LY2439821, an anti-interleukin-17 monoclonal antibody, given subcutaneously in patients with moderate to severe psoriasis
    Leonardi, C.
    Matheson, R.
    Zachariae, C.
    Cameron, G.
    Li, L.
    Edson, E.
    Braun, D.
    Banerjee, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E18 - E19
  • [27] Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition
    Napolitano, M.
    Megna, M.
    Fabbrocini, G.
    Nistico, S. P.
    Balato, N.
    Dastoli, S.
    Patruno, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (03) : 604 - 606
  • [28] Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study
    Ruggiero, Angelo
    Fabbrocini, Gabriella
    Cinelli, Eleonora
    Megna, Matteo
    DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [29] Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis
    Papp, Kim A.
    Leonardi, Craig
    Menter, Alan
    Ortonne, Jean-Paul
    Krueger, James G.
    Kricorian, Gregory
    Aras, Girish
    Li, Juan
    Russell, Chris B.
    Thompson, Elizabeth H. Z.
    Baumgartner, Scott
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (13): : 1181 - 1189
  • [30] Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody
    Genovese, Mark C.
    Mease, Philip
    Greenwald, Maria W.
    Ritchlin, Christopher T.
    Beaulieu, A.
    Deodhar, Atul A.
    Newmark, Richard
    Feng, JingYuan
    Erondu, Ngozi
    Nirula, Ajay
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S687 - S687
12345